MAFSelexipag Tablet 200 mcg, 400 mcg, 600 mcg, 800 mcg
To be added as the second or third drug in a combination treatment for pulmonary arterial hypertension (PAH), in line with the following criteria:
• Patient is already receiving an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor at maximum tolerated doses; and
• Prior to adding selexipag treatment, patient is assessed to have intermediate to high risk of 1-year mortality (according to the European Society of Cardiology/European Respiratory Society risk-stratification tool) during follow-up.